These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 6804110)

  • 81. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients.
    Fananapazir L; Tracy CM; Leon MB; Winkler JB; Cannon RO; Bonow RO; Maron BJ; Epstein SE
    Circulation; 1989 Nov; 80(5):1259-68. PubMed ID: 2805263
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Encainide.
    Antonaccio MJ; Gomoll AW; Byrne JE
    Cardiovasc Drugs Ther; 1989 Oct; 3(5):691-710. PubMed ID: 2518680
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Canine electrophysiology of encainide, a new antiarrhythmic drug.
    Sami M; Mason JW; Oh G; Harrison DC
    Am J Cardiol; 1979 Jun; 43(6):1149-54. PubMed ID: 443174
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Prevalence, characteristics and significance of ventricular premature complexes and ventricular tachycardia detected by 24-hour continuous electrocardiographic recording in the Cardiac Arrhythmia Suppression Trial. CAST Investigators.
    Denes P; Gillis AM; Pawitan Y; Kammerling JM; Wilhelmsen L; Salerno DM
    Am J Cardiol; 1991 Oct; 68(9):887-96. PubMed ID: 1718158
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Encainide for resistant supraventricular tachycardia in children: follow-up report.
    Strasburger JF; Smith RT; Moak JP; Gothing C; Garson A
    Am J Cardiol; 1988 Dec; 62(19):50L-54L. PubMed ID: 3144168
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Electrophysiologic effects of ethmozin in patients with ventricular tachycardia.
    Mann DE; Luck JC; Herre JM; Magro SA; Yepsen SC; Griffin JC; Pratt CM; Wyndham CR
    Am Heart J; 1984 Apr; 107(4):674-9. PubMed ID: 6367405
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Encainide hydrochloride and flecainide acetate: two class 1c antiarrhythmic agents.
    Chase SL; Sloskey GE
    Clin Pharm; 1987 Nov; 6(11):839-50. PubMed ID: 3119276
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Effect of moricizine hydrochloride in reducing chronic high-frequency ventricular arrhythmia: results of a prospective, controlled trial.
    Singh SN; DiBianco R; Gottdiener JS; Ginsberg R; Fletcher RD
    Am J Cardiol; 1984 Mar; 53(6):745-50. PubMed ID: 6367416
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Heart rate variability in patients suffering from structural heart disease and decreased AV-nodal conduction capacity. Insights into the formation of heart rate variability.
    Schwab JO; Eichner G; Schmitt H; Schrickel J; Yang A; Balta O; Lüderitz B; Lewalter T
    Z Kardiol; 2004 Mar; 93(3):229-33. PubMed ID: 15024591
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Encainide: its electrophysiologic and antiarrhythmic effects, pharmacokinetics, and safety.
    Tordjman T; Estes NA
    Pharmacotherapy; 1987; 7(5):149-63. PubMed ID: 3124082
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Encainide: a new and potent antiarrhythmic.
    Somberg JC; Zanger D; Levine E; Tepper D
    Am Heart J; 1987 Oct; 114(4 Pt 1):826-35. PubMed ID: 3116833
    [No Abstract]   [Full Text] [Related]  

  • 92. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
    Echt DS; Liebson PR; Mitchell LB; Peters RW; Obias-Manno D; Barker AH; Arensberg D; Baker A; Friedman L; Greene HL
    N Engl J Med; 1991 Mar; 324(12):781-8. PubMed ID: 1900101
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Clinical efficacy and electrophysiologic effects of cibenzoline therapy in patients with ventricular arrhythmias.
    Browne KF; Prystowsky EN; Zipes DP; Chilson DA; Heger JJ
    J Am Coll Cardiol; 1984 Mar; 3(3):857-64. PubMed ID: 6693656
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Encainide: a new and potent antiarrhythmic agent.
    Harrison DC; Winkle R; Sami M; Mason J
    Am Heart J; 1980 Dec; 100(6 Pt 2):1046-54. PubMed ID: 6778194
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Encainide for treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome.
    Markel ML; Prystowsky EN; Heger JJ; Miles WM; Fineberg N; Zipes DP
    Am J Cardiol; 1986 Aug; 58(5):41C-48C. PubMed ID: 3092619
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Antiarrhythmic effects of oral indecainide in patients with ventricular tachyarrhythmias.
    Macina G; Turitto G; Stavens C; Fontaine J; Hariman R; Ursell S; el-Sherif N
    Clin Cardiol; 1987 Jun; 10(6):357-61. PubMed ID: 3594958
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Comparison of the efficacy of newly developed antiarrhythmic drugs in the treatment of ventricular tachyarrhythmias.
    Hellestrand KJ
    Eur Heart J; 1984 Sep; 5 Suppl B():87-94. PubMed ID: 6437822
    [No Abstract]   [Full Text] [Related]  

  • 98. Acute effects of combination of IB and IC antiarrhythmics for the treatment of ventricular tachycardia.
    Bleske BE; Kluger J; Fisher J; Chow MS
    J Clin Pharmacol; 1989 Nov; 29(11):998-1002. PubMed ID: 2513339
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man.
    Barbey JT; Thompson KA; Echt DS; Woosley RL; Roden DM
    Circulation; 1988 Feb; 77(2):380-91. PubMed ID: 3123092
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: a comparative study with sotalol and encainide.
    Buchanan LV; Kabell G; Turcotte UM; Brunden MN; Gibson JK
    J Cardiovasc Pharmacol; 1992 Feb; 19(2):256-63. PubMed ID: 1376795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.